Twenty-five evaluable, ambulatory outpatients with disseminated malignant melanoma received tamoxifen at a dose of 40 mg orally each day. None of the patients had an objective regression and approximately 70% had disease progression within 30 days of starting treatment, including two patients with detectable estrogen receptor titers. Median survival time and time to progression were 4 months and 1 month respectively. Performance score was the most significant covariate for survival time (P<0.01) and time to progression (P = 0.02).
|Original language||English (US)|
|Number of pages||3|
|Journal||Cancer Treatment Reports|
|State||Published - Nov 18 1980|
ASJC Scopus subject areas
- Cancer Research